Thames Valley

Oxford BioTherapeutics wins Tech Company of the Year and Special Recognition Award at Thames Valley SME Growth 100 Awards

Retrieved on: 
Tuesday, March 7, 2023
Partnership, ADC, Growth, Map, Business development, Mass spectrometry, Cancer, Therapy, Conjugation, Patient, SME, Antibody-drug conjugate, OBT, Senior, The Business, Fine chemical, Management, Operation, Thames Valley

Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.

Key Points: 
  • Oxford, UK and San Jose, Calif., 7 March 2023- Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody-Drug Conjugate (ADC)-based therapies, announces it has been honoured with two prestigious awards: the ‘Tech Company of the Year’ and the ‘Special Recognition Award’, at The Business Magazine’s fourth annual Thames Valley SME Growth 100 Awards.
  • These awards celebrate the region's most active small and medium-sized enterprises (SMEs) that have grown significantly in the past year.
  • The ‘Tech Company of the Year’ award recognises exceptional use of technology to advance company objectives, improve communities and/or empower clients.
  • This company’s ground-breaking achievements make them a very worthy winner.”
    “We are honoured to have received these awards,” said Christian Rohlff, CEO at Oxford BioTherapeutics.

Sleepio Is the First-Ever Digital Therapeutic to Receive NICE Guidance, Confirming Clinical and Cost Effectiveness

Retrieved on: 
Friday, May 20, 2022
Managed Care, General Health, Health, Mental Health, NHS, Insomnia, Digital, Smartphone, Self-management, National Institute for Health and Care Excellence, CBT, Isabella Tree, Generalized anxiety disorder, Ageing, Regulation of tobacco by the U.S. Food and Drug Administration, Policy, Food, National Institute, Board of directors, Patient, Oxford Health NHS Foundation Trust, CE, UnitedHealth Group, NICE, United Kingdom, FDA, Thames Valley, Anxiety, National Health Service (England), Innovation, Standard of care, Therapy, Innovate UK, Sleep hygiene, Mental health, Lists of diseases, Oxford, Diagnosis, Committee, National Health Service, Web browser, CEO, Pharmaceutical industry, Health insurance, Medical device, Medicine, Sleepio

Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.

Key Points: 
  • Peer-reviewed clinical trials show Sleepio helps 76% of patients to achieve clinical improvement in insomnia.
  • Big Health co-founder and Chief Scientist Professor Colin Espie said: We are delighted that Sleepio has become the first-ever digital therapeutic to receive NICE guidance after rigorous evaluation.
  • Digital therapeutics arent wellness apps; they are proper treatments backed by data and clinical evidence, fit for assessment by world-leading bodies like NICE.
  • Sleepio is a clinically-evidenced digital therapeutic for insomnia developed by world-renowned clinical psychologist and sleep expert Professor Colin Espie.